Verification of the psychometric properties of the Slovak version of the Dementia Rating Scale-2 in a healthy population and in patients with Parkinson‘s disease – a pilot study

Česká verze

Authors: V. Boleková ^1,2; P. Brandoburová ^1,3,4; M. Hajdúk ^3,5,6; I. Straka ¹; P. Valkovič ^1,7; Z. Košutzká ^1*
Authors place of work: II. neurologická klinika LF UK a UNB, Bratislava, SR ¹; Ústav klinickej psychológie, Fakulta psychológie, Paneurópska vysoká škola, Bratislava, SR ²; Katedra psychológie, Filozofická fakulta UK, Bratislava, SR ³; Centrum MEMORY n. o., Bratislava, SR ⁴; Psychiatrická klinika LF UK a UNB, Bratislava, SR ⁵; Centrum výskumu psychických porúch UK, Bratislava, SR ⁶; Ústav normálnej a patologickej fyziológie, Centrum experimentálnej medicíny Slovenskej akadémie vied, Bratislava, SR ⁷
Published in the journal: Cesk Slov Neurol N 2023; 86(3): 185-192
Category: Původní práce
doi: https://doi.org/10.48095/cccsnn2023185

Summary

Aim: Aims of this study were to verify the psychometric characteristics of the Slovak version of the Mattis Dementia Rating Scale-2 (DRS-2), examine its diagnostic accuracy in the population of patients with Parkinson‘s disease (PD), and establish a preliminary cut-off score for the diagnosis of mild cognitive impairment (MCI). Sample and methods: The clinical population consisted of 30 patients with PD with an average duration of the disease of 5.53 ± 3.92 years. Eleven patients were diagnosed with MCI. The control group of healthy people without neurological disease consisted of 43 participants who were age and education matched. All participants were administered the Slovak version of the DRS-2 measuring attention, memory, initiation/ perseveration, construction skills and conceptualization. A comprehensive neuropsychological battery was used to assess convergent validity. Results: Correlations of DRS-2 scores with a screening tools and analogous tests of the neuropsychological battery indicate good convergent validity of the tool (with the exception of the construction subtest). We found the strongest relationships for the initiation/perseveration and memory subtests. Furthermore, we objectified a good discriminative power in patients with PD without cognitive deficits and patients with MCI with the determination of an optimal cut-off score of 134 points (sensitivity 81.80% and specificity 89.50%). Conclusion: The Slovak version of the DRS-2 is an instrument with satisfactory psychometric properties and can potentially be used to test cognition in the healthy population and patients with Parkinson‘s disease.

Keywords:

Cognition – Psychometrics – Parkinson‘s disease – Dementia Rating Scale-2

Zdroje

1. Jurica PJ, Leitten CL, Mattis S. Dementia Rating Scale-2. Psychological Assessments Recources 2001.

2. Marson DC, Dymek MP, Duke LW et al. Subscale validity of the Mattis Dementia Rating Scale. Arch Clin Neuropsychol 1997; 12(3): 269–275.

3. Chou KL, Amick MM, Brandt J et al. A recommended scale for cognitive screening in clinical trials of Parkinson‘s disease. Mov Disord 2010; 25(15): 2501–2507. doi: 10.1002/ mds.23362.

4. Skorvanek M, Goldman JG, Jahanshahi M et al. Global scales for cognitive screening in Parkinson‘s disease: critique and recommendations. Mov Disord 2018; 33(2): 208–218. doi: 10.1002/ mds.27233.

5. Baiano C, Barone P, Trojano L et al. Prevalence and clinical aspects of mild cognitive impairment in Parkinson‘s disease: a meta-analysis. Mov Disord 2020; 35(1): 45–54. doi: 10.1002/ mds.27902.

6. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson‘s disease. Lancet Neurol 2010; 9(12): 1200–1213. doi: 10.1016/ S1474-4422(10)70212-X.

7. Deuschl G, Schade-Brittinger C, Krack P et al. A randomized trial of deep-brain stimulation for Parkinson‘s disease. N Engl J Med 2006; 355(9): 896–908. doi: 10.1056/ NEJMoa060281.

8. Bezdicek O, Michalec J, Nikolai T et al. Clinical validity of the Mattis Dementia Rating Scale in differentiating mild cognitive impairment in Parkinson‘s disease and normative data. Dement Geriatr Cogn Disord 2015; 39 (5–6): 303–311. doi: 10.1159/ 000375365.

9. Brown GG, Rahill AA, Gorell JM et al. Validity of the Dementia Rating Scale in assessing cognitive function in Parkinson‘s disease. J Geriatr Psychiatry Neurol 1999; 12(4): 180–188. doi: 10.1177/ 089198879901200 403.

10. Villeneuve S, Rodrigues-Brazète J, Joncas S et al. Validity of the Mattis Dementia Rating Scale to detect mild cognitive impairment in Parkinson‘s disease and REM sleep behavior disorder. Dement Geriatr Cogn Disord 2011; 31(3): 210–217. doi: 10.1159/ 000326212.

11. Schmidt KS, Mattis PJ, Adams J et al. Alternate-form reliability of the Dementia Rating Scale-2. Arch Clin Neuropsychol 2005; 20(4): 435–441. doi: 10.1016/ j.acn. 2004.09.011.

12. Boycheva E, Contador I, Fernández-Calvo B et al. Spanish version of the Mattis Dementia Rating Scale-2 for early detection of Alzheimer‘s disease and mild cognitive impairment. Int J Geriatr Psychiatry 2018; 33(6): 832–840. doi: 10.1002/ gps.4707.

13. Kaszás B, Kovács N, Balás I et al. Sensitivity and specificity of Addenbrooke‘s Cognitive Examination, Mattis Dementia Rating Scale, Frontal Assessment Battery and Mini Mental State Examination for diagnosing dementia in Parkinson‘s disease. Parkinsonism Relat Disord 2012; 18(5): 553–556. doi: 10.1016/ j.parkreldis.2012.02. 010.

14. Lyness SA, Hernandez I, Chui HC et al. Performance of Spanish speakers on the Mattis dementia rating scale (MDRS). Arch Clin Neuropsychol 2006; 21(8): 827–836. doi: 10.1016/ j.acn.2006.09.003.

15. Pirogovsky E, Schiehser DM, Litvan I et al. The utility of the Mattis Dementia Rating Scale in Parkinson‘s disease mild cognitive impairment. Parkinsonism Relat Disord 2014; 20(6): 627–631. doi: 10.1016/ j.parkreldis.2014.03. 010.

16. Koevoets EW, Schmand B, Geurtsen GJ. Accuracy of two cognitive screening tools to detect mild cognitive impairment in Parkinson‘s disease. Mov Disord Clin Pract 2018; 5(3): 259–264. doi: 10.1002/ mdc3.12597.

17. Mazancova AF, Růžička E, Jech R et al. Test the best: classification accuracies of four cognitive rating scales for Parkinson‘s disease mild cognitive impairment. Arch Clin Neuropsychol 2020; acaa039. doi: 10.1093/ arclin/ acaa039.

18. Matteau E, Dupré N, Simard M. Detection of mild cognitive impairment in idiopathic Parkinson‘s disease with the Mattis Dementia Rating Scale. Alzheimers Dement 2008; 4(4): 267.

19. Llebaria G, Pagonabarraga J, Kulisevsky J et al. Cut-off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson‘s disease. Mov Disord 2008; 23(11): 1546–1550. doi: 10.1002/ mds.22173.

20. Lavoie M, Callahan B, Belleville S et al. Normative data for the Dementia Rating Scale-2 in the French-Quebec population. Clin Neuropsychol 2013; 27(7): 1150–1166. doi: 10.1080/ 13854046.2013.825010.

21. Pedraza O, Lucas JA, Smith GE et al. Robust and expanded norms for the Dementia Rating Scale. Arch Clin Neuropsychol 2010; 25(5): 347–358. doi: 10.1093/ arclin/ acq030.

22. Rilling LM, Lucas JA, Ivnik RJ et al. Mayo‘s Older African American Normative Studies: norms for the Mattis Dementia Rating Scale. Clin Neuropsychol 2005; 19(2): 229–242. doi: 10.1080/ 13854040590945 328.

23. Strutt AM, Ayanegui IG, Scott BM et al. Influence of socio-demographic characteristics on DRS-2 performance in Spanish-speaking older adults. Arch Clin Neuropsychol 2012; 27(5): 545–556. doi: 10.1093/ arclin/ acs 049.

24. Pontone GM, Palanci J, Williams JR et al. Screening for DSM-IV-TR cognitive disorder NOS in Parkinson‘s disease using the Mattis Dementia Rating Scale. Int J Geriatr Psychiatry 2013; 28(4): 364–371. doi: 10.1002/ gps.3833.

25. Goetz CG, Poewe W, Rascol O et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004; 19(9): 1020–1028. doi: 10.1002/ mds.20213.

26. Postuma RB, Berg D, Stern M et al. MDS clinical diagnostic criteria for Parkinson‘s disease. Mov Disord 2015; 30(12): 1591–1601. doi: 10.1002/ mds.26424.

27. Goetz CG, Tilley BC, Shaftman SR et al. Movement Disorder Society-sponsored revision of the Unified Parkinson‘s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23(15): 2129–2170. doi: 10.1002/ mds.22 340.

28. Tomlinson CL, Stowe R, Patel S et al. Systematic review of levodopa dose equivalency reporting in Parkinson‘s disease. Mov Disord 2010; 25(15): 2649–2653. doi: 10.1002/ mds.23429.

29. Hajdúk M, Brandoburová P, Pribišová K et al. NEUROPSY: Štandardizácia neuropsychologickej testovej batérie na dospelej slovenskej populácii. Bratislava: Univerzita Komenského v Bratislave 2021.

30. Beaton DE, Bombardier C, Guillemin F et al. Guidelines for the process of cross-cultural adaptation of self--report measures. Spine 2000; 25(24): 3186–3191. doi: 10.1097/ 00007632-200012150-00014.

31. Franzen S, Papma JM, van den Berg E et al. Cross- -cultural neuropsychological assessment in the European Union: a Delphi expert study. Arch Clin Neuropsychol 2021; 36(5): 815–830. doi: 10.1093/ arclin/ acaa 083.

32. Litvan I, Goldman JG, Tröster AI et al. Diagnostic criteria for mild cognitive impairment in Parkinson‘s disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27(3): 349–356. doi: 10.1002/ mds.24 893.

33. Chan AS, Choi MK, Salmon DP. The effects of age, education, and gender on the Mattis Dementia Rating Scale performance of elderly Chinese and American individuals. J Gerontol B Psychol Sci Soc Sci 2001; 56(6): P356–363. doi: 10.1093/ geronb/ 56.6.p356.